The estimated Net Worth of Sharon W Klugewicz is at least $62.8 millier dollars as of 20 May 2020. Sharon Klugewicz owns over 825 units of Misonix Inc stock worth over $37,554 and over the last 11 years Sharon sold MSON stock worth over $25,200.
Sharon has made over 7 trades of the Misonix Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Sharon bought 825 units of MSON stock worth $10,032 on 20 May 2020.
The largest trade Sharon's ever made was buying 10,000 units of Misonix Inc stock on 26 February 2014 worth over $35,000. On average, Sharon trades about 1,924 units every 152 days since 2014. As of 20 May 2020 Sharon still owns at least 1,415 units of Misonix Inc stock.
You can see the complete history of Sharon Klugewicz stock trades at the bottom of the page.
Sharon's mailing address filed with the SEC is C/O MISONIX, INC., 1938 NEW HIGHWAY, FARMINGDALE, NY, 11735.
Over the last 21 years, insiders at Misonix Inc have traded over $4,371,211 worth of Misonix Inc stock and bought 1,536,334 units worth $6,620,934 . The most active insiders traders include Stavros G. Vizirgianakis, Gary Gelman et Michael A Jr Mcmanus. On average, Misonix Inc executives and independent directors trade stock every 29 days with the average trade being worth of $378,885. The most recent stock trade was executed by Sharon W Klugewicz on 20 May 2020, trading 825 units of MSON stock currently worth $10,032.
Misonix, Inc. is a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative tissue products. Its surgical team markets and sells BoneScalpel and SonaStar, which facilitate precise bone sculpting and removal of soft and hard tumors and tissue, primarily in the areas of neurosurgery, orthopedic, plastic and maxillo-facial surgery. The Company's wound team markets and sells TheraSkin, Therion, TheraGenesis and SonicOne to debride, treat and heal chronic and traumatic wounds in inpatient, outpatient and physician office sites of service. At Misonix, Better Matters! That is why throughout the Company's history, Misonix has maintained its commitment to medical technology innovation and the development of products that radically improve outcomes for patients.
Misonix Inc executives and other stock owners filed with the SEC include: